I carefully listened to the CEO's presentation and rewinded some segments a number of times to make sure I clearly understood what he said. One of his statements got my attention. Feel free to respond and confirm if I understood the following correctly:
1. Did he say that patients will continue to be on Arikayce for another 84 (for a today of 168 days) and additional patients (besides the 11) have already demonstrated culture conversion to negative (i.e., cured)?
2. If so, since the reduction in bacterial density was "numerically superior, not statistically significant", isn't there a chance with the continued study that statistical significance could be attained if the trending in reduction of bacterial density continues among patients?